Legato Capital Management LLC bought a new position in shares of Merus (NASDAQ:MRUS – Free Report) in the second quarter, Holdings Channel.com reports. The fund bought 10,403 shares of the biotechnology company’s stock, valued at approximately $616,000.
Other large investors have also modified their holdings of the company. Great Point Partners LLC purchased a new stake in shares of Merus during the fourth quarter worth $550,000. BNP Paribas Financial Markets grew its holdings in shares of Merus by 63.8% during the first quarter. BNP Paribas Financial Markets now owns 102,885 shares of the biotechnology company’s stock worth $4,633,000 after buying an additional 40,060 shares in the last quarter. Trexquant Investment LP grew its holdings in shares of Merus by 138.4% during the fourth quarter. Trexquant Investment LP now owns 40,489 shares of the biotechnology company’s stock worth $1,113,000 after buying an additional 23,503 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Merus during the fourth quarter worth $1,320,000. Finally, Avoro Capital Advisors LLC grew its holdings in shares of Merus by 100.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 888,888 shares of the biotechnology company’s stock worth $24,444,000 after buying an additional 444,444 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.
Insider Buying and Selling at Merus
In other Merus news, VP Harry Shuman sold 6,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $52.89, for a total value of $317,340.00. Following the transaction, the vice president now directly owns 7,002 shares in the company, valued at $370,335.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Peter B. Silverman sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Harry Shuman sold 6,000 shares of the firm’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $52.89, for a total value of $317,340.00. Following the completion of the transaction, the vice president now owns 7,002 shares of the company’s stock, valued at approximately $370,335.78. The disclosure for this sale can be found here. Insiders have sold 24,300 shares of company stock worth $1,392,792 over the last three months. Insiders own 4.57% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on MRUS
Merus Stock Performance
Shares of MRUS opened at $53.01 on Wednesday. The stock has a market capitalization of $3.11 billion, a PE ratio of -19.14 and a beta of 1.12. Merus has a 1 year low of $19.81 and a 1 year high of $61.61. The company’s 50-day simple moving average is $54.09 and its 200-day simple moving average is $49.51.
Merus (NASDAQ:MRUS – Get Free Report) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). The firm had revenue of $7.33 million for the quarter, compared to analysts’ expectations of $9.64 million. Merus had a negative return on equity of 45.76% and a negative net margin of 476.41%. On average, sell-side analysts predict that Merus will post -3.05 earnings per share for the current year.
Merus Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
- Five stocks we like better than Merus
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Sleeper AI-Winner Ambarella Will More Than Triple in Price
- Technology Stocks Explained: Here’s What to Know About Tech
- Gold vs. Silver: Which Is the Better Investment in the New Cycle?
- 3 Warren Buffett Stocks to Buy Now
- 3 Best Growth Stocks to Own for the Next 10 Years
Want to see what other hedge funds are holding MRUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merus (NASDAQ:MRUS – Free Report).
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.